PRIME II ‘extremely reassuring’ on radiotherapy omission in older women with early breast cancer
The 10-year data from the PRIME II trial suggest that radiotherapy after breast-conserving surgery can be omitted for women aged 65 years or older with low-risk, hormone receptor-positive early breast cancer.
